Literature DB >> 19185846

Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment.

Marcin Kortylewski1, Hong Xin, Maciej Kujawski, Heehyoung Lee, Yong Liu, Timothy Harris, Charles Drake, Drew Pardoll, Hua Yu.   

Abstract

Interactions between tumor and immune cells either enhance or inhibit cancer progression. We show here that Stat3 signaling within the tumor microenvironment induces a procarcinogenic cytokine, IL-23, while inhibiting a central anticarcinogenic cytokine, IL-12, thereby shifting the balance of tumor immunity toward carcinogenesis. Stat3 induces expression of IL-23, which is mainly produced by tumor-associated macrophages, via direct transcriptional activation of the IL-23/p19 gene. Furthermore, Stat3 inhibits NF-kappaB/c-Rel-dependent IL-12/p35 gene expression in tumor-associated dendritic cells. Tumor-associated regulatory T cells (Tregs) express IL-23 receptor, which activates Stat3 in this cell type, leading to upregulation of the Treg-specific transcription factor Foxp3 and the immunosuppressive cytokine IL-10. These results demonstrate that Stat3 promotes IL-23-mediated procarcinogenic immune responses while inhibiting IL-12-dependent antitumor immunity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19185846      PMCID: PMC2673504          DOI: 10.1016/j.ccr.2008.12.018

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  44 in total

1.  IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.

Authors:  V Shankaran; H Ikeda; A T Bruce; J M White; P E Swanson; L J Old; R D Schreiber
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

2.  Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.

Authors:  B Oppmann; R Lesley; B Blom; J C Timans; Y Xu; B Hunte; F Vega; N Yu; J Wang; K Singh; F Zonin; E Vaisberg; T Churakova; M Liu; D Gorman; J Wagner; S Zurawski; Y Liu; J S Abrams; K W Moore; D Rennick; R de Waal-Malefyt; C Hannum; J F Bazan; R A Kastelein
Journal:  Immunity       Date:  2000-11       Impact factor: 31.745

3.  Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10.

Authors:  Jason S Stumhofer; Jonathan S Silver; Arian Laurence; Paige M Porrett; Tajie H Harris; Laurence A Turka; Matthias Ernst; Christiaan J M Saris; John J O'Shea; Christopher A Hunter
Journal:  Nat Immunol       Date:  2007-11-11       Impact factor: 25.606

4.  IL-27 inhibits the development of regulatory T cells via STAT3.

Authors:  Magdalena Huber; Vera Steinwald; Anna Guralnik; Anne Brüstle; Peter Kleemann; Christine Rosenplänter; Thomas Decker; Michael Lohoff
Journal:  Int Immunol       Date:  2007-12-21       Impact factor: 4.823

5.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

6.  IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner.

Authors:  Lai Wei; Arian Laurence; Kevin M Elias; John J O'Shea
Journal:  J Biol Chem       Date:  2007-09-20       Impact factor: 5.157

Review 7.  Cytokine signaling modules in inflammatory responses.

Authors:  John J O'Shea; Peter J Murray
Journal:  Immunity       Date:  2008-04       Impact factor: 31.745

8.  Reciprocal activating interaction between natural killer cells and dendritic cells.

Authors:  Franca Gerosa; Barbara Baldani-Guerra; Carla Nisii; Viviana Marchesini; Giuseppe Carra; Giorgio Trinchieri
Journal:  J Exp Med       Date:  2002-02-04       Impact factor: 14.307

9.  Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.

Authors:  R P Sutmuller; L M van Duivenvoorde; A van Elsas; T N Schumacher; M E Wildenberg; J P Allison; R E Toes; R Offringa; C J Melief
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

10.  c-Rel regulates interleukin 12 p70 expression in CD8(+) dendritic cells by specifically inducing p35 gene transcription.

Authors:  R Grumont; H Hochrein; M O'Keeffe; R Gugasyan; C White; I Caminschi; W Cook; S Gerondakis
Journal:  J Exp Med       Date:  2001-10-15       Impact factor: 14.307

View more
  210 in total

1.  Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses.

Authors:  Ling-Yuan Kong; Adam S Wu; Tiffany Doucette; Jun Wei; Waldemar Priebe; Gregory N Fuller; Wei Qiao; Raymond Sawaya; Ganesh Rao; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2010-10-04       Impact factor: 12.531

Review 2.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 3.  Up for Mischief? IL-17/Th17 in the tumour microenvironment.

Authors:  E Maniati; R Soper; T Hagemann
Journal:  Oncogene       Date:  2010-08-23       Impact factor: 9.867

Review 4.  Dual roles for immunity in gastrointestinal cancers.

Authors:  Cristina Ferrone; Glenn Dranoff
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

5.  Engineered Materials for Cancer Immunotherapy.

Authors:  Alexander S Cheung; David J Mooney
Journal:  Nano Today       Date:  2015-08-01       Impact factor: 20.722

Review 6.  Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment.

Authors:  Yunlu Dai; Can Xu; Xiaolian Sun; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2017-05-18       Impact factor: 54.564

Review 7.  Role of the tumor microenvironment in the pathogenesis of gastric carcinoma.

Authors:  Hye Won Chung; Jong-Baeck Lim
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

8.  Differential regulation of interleukin-12 (IL-12)/IL-23 by Tim-3 drives T(H)17 cell development during hepatitis C virus infection.

Authors:  Jia M Wang; Lei Shi; Cheng J Ma; Xiao J Ji; Ruo S Ying; Xiao Y Wu; Ke S Wang; Guangyu Li; Jonathan P Moorman; Zhi Q Yao
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

9.  Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation.

Authors:  C Andrew Stewart; Hannah Metheny; Noriho Iida; Loretta Smith; Miranda Hanson; Folkert Steinhagen; Robert M Leighty; Axel Roers; Christopher L Karp; Werner Müller; Giorgio Trinchieri
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

10.  Tim-3 alters the balance of IL-12/IL-23 and drives TH17 cells: role in hepatitis B vaccine failure during hepatitis C infection.

Authors:  Jia M Wang; Cheng J Ma; Guang Y Li; Xiao Y Wu; Penny Thayer; Pamela Greer; Ashley M Smith; Kevin P High; Jonathan P Moorman; Zhi Q Yao
Journal:  Vaccine       Date:  2013-03-14       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.